Penumbra (NYSE:PEN) EVP Johanna Roberts Sells 300 Shares

Penumbra, Inc. (NYSE:PEN) EVP Johanna Roberts sold 300 shares of the firm’s stock in a transaction dated Friday, December 5th. The stock was sold at an average price of $300.13, for a total value of $90,039.00. Following the transaction, the executive vice president owned 63,836 shares of the company’s stock, valued at $19,159,098.68. This trade represents a 0.47% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Johanna Roberts also recently made the following trade(s):

• On Monday, December 1st, Johanna Roberts sold 600 shares of Penumbra stock. The shares were sold at an average price of $294.94, for a total value of $176,964.00.
• On Tuesday, November 25th, Johanna Roberts sold 1,800 shares of Penumbra stock. The shares were sold at an average price of $300.06, for a total transaction of $540,108.00.
• On Monday, November 10th, Johanna Roberts sold 600 shares of Penumbra stock. The stock was sold at an average price of $266.98, for a total transaction of $160,188.00.
• On Wednesday, October 1st, Johanna Roberts sold 600 shares of Penumbra stock. The shares were sold at an average price of $249.70, for a total transaction of $149,820.00.

Penumbra Trading Down 2.6%

NYSE PEN traded down $7.72 during mid-day trading on Tuesday, reaching $287.11. 551,940 shares of the stock were exchanged, compared to its average volume of 452,942. The stock has a market cap of $11.24 billion, a P/E ratio of 68.69, a P/E/G ratio of 2.43 and a beta of 0.66. The company has a debt-to-equity ratio of 0.02, a current ratio of 6.73 and a quick ratio of 4.18. Penumbra, Inc. has a one year low of $221.26 and a one year high of $310.00. The stock has a 50 day simple moving average of $265.68 and a 200-day simple moving average of $258.25.

Penumbra (NYSE:PEN) last issued its quarterly earnings results on Wednesday, November 5th. The company reported $0.97 EPS for the quarter, beating analysts’ consensus estimates of $0.90 by $0.07. Penumbra had a net margin of 12.30% and a return on equity of 11.35%. The business had revenue of $354.69 million for the quarter, compared to analysts’ expectations of $340.77 million. During the same quarter in the prior year, the firm posted $0.85 earnings per share. The business’s quarterly revenue was up 17.8% compared to the same quarter last year. On average, analysts anticipate that Penumbra, Inc. will post 3.67 EPS for the current year.

Institutional Investors Weigh In On Penumbra

Institutional investors and hedge funds have recently bought and sold shares of the stock. Vanguard Group Inc. boosted its holdings in Penumbra by 5.0% during the 2nd quarter. Vanguard Group Inc. now owns 3,860,655 shares of the company’s stock worth $990,760,000 after acquiring an additional 185,306 shares during the last quarter. Geode Capital Management LLC raised its holdings in shares of Penumbra by 2.6% in the second quarter. Geode Capital Management LLC now owns 706,404 shares of the company’s stock valued at $181,314,000 after purchasing an additional 17,772 shares during the last quarter. JPMorgan Chase & Co. raised its holdings in shares of Penumbra by 437.0% in the first quarter. JPMorgan Chase & Co. now owns 703,634 shares of the company’s stock valued at $188,159,000 after purchasing an additional 572,606 shares during the last quarter. Invesco Ltd. lifted its position in shares of Penumbra by 1,139.3% during the second quarter. Invesco Ltd. now owns 633,485 shares of the company’s stock valued at $162,571,000 after purchasing an additional 582,369 shares in the last quarter. Finally, Norges Bank purchased a new position in Penumbra during the second quarter worth about $114,014,000. 88.88% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of brokerages have weighed in on PEN. Wells Fargo & Company started coverage on Penumbra in a report on Tuesday, November 18th. They issued an “underweight” rating for the company. Truist Financial reduced their price objective on shares of Penumbra from $310.00 to $300.00 and set a “buy” rating for the company in a research report on Wednesday, October 15th. Needham & Company LLC reiterated a “buy” rating and set a $326.00 target price on shares of Penumbra in a research report on Monday, October 27th. JPMorgan Chase & Co. raised their price target on shares of Penumbra from $265.00 to $275.00 and gave the stock a “neutral” rating in a report on Thursday, November 6th. Finally, Wall Street Zen cut shares of Penumbra from a “buy” rating to a “hold” rating in a research report on Saturday, November 1st. One equities research analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating, four have issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $305.69.

Penumbra Company Profile

Penumbra, Inc, together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. The company offers peripheral products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX.